ArticleFrontiers in medicine2025
The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hemolytic anemia (AIHA) is a type of hemolytic anemia. In this condition, the body produces anti-red blood cell autoantibodies due to immune dysfunction. This results in accelerated destruction of red blood cells. According to the best temperature for autoantibodies to stick to red blood cells, there are three types: warm antibody type (wAIHA), cold antibody type (cAIHA), and mixed warm-cold antibody type (mAIHA). This article presents a case of acute severe warm antibody autoimmune hemolytic anemia in an elderly male patient. The patient exhibited symptoms including jaundice of the skin, mucous membranes, and urine with a soy sauce color. Laboratory tests were as follows: hemoglobin (HGB) as low as 31 g/L; indirect bilirubin (IBIL) as high as 162 μmol/L; lactate dehydrogenase (LDH) level as high as 1,295 IU/L; reticulocyte percentage (RET%) > 4%; Coombs test positive; conjugated beads protein assay < 0.2 g/L; direct anti-human globulin test positive; indirect anti-human globulin test positive; anti-IgG+++; anti-C3d negative; cold agglutinin test (CAT) negative. After admission, the patient was given a combination of two treatments: methylprednisolone and immunoglobulin. During the treatment, the patient developed a hemolytic crisis. He was immediately given iptacopan and high-dose glucocorticoid shock therapy. After treatment, the patient's hemolytic-related symptoms improved rapidly. The hemoglobin levels remained within a safe range after stopping the blood transfusion. It is reported as follows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.